7 completed, 1 withdrawn. 5 Phase 2, 3 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 3 |
| Not applicable | 1 | Withdrawn 1 |
Follow B3(Fv)-PE38KDEL recombinant immunotoxin: new trials by email Literature Review of B3(Fv)-PE38KDEL recombinant immunotoxin trials Research Report on B3(Fv)-PE38KDEL recombinant immunotoxin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia LMB-2, Fludarabine, Cyclophosphamide - Adult T-Cell Leukemia (ATL) | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2008-10-31 | 2023-11-14 |
| Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma LMB-2 immunotoxin, cyclophosphamide, fludarabine phosphate - Lymphoma | Not applicable | Withdrawn | National Institutes of Health Clinical Center (CC) | 2006-09-01 | 2012-03-16 | |
| LMB-2 to Treat Hairy Cell Leukemia Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin - Hairy Cell Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2006-05-02 | 2023-11-14 |
| LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery LMB-2 immunotoxin, MART-1 antigen, gp100 antigen - Melanoma (Skin), Non-melanomatous Skin Cancer | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 26 | 2005-12-01 | 2012-06-14 |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas LMB-2 - Lymphoma, T-Cell | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2004-04-30 | 2018-01-29 |
| LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma LMB-2 immunotoxin - Leukemia, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-04-01 | 2015-04-30 |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia LMB-2 - Leukemia, Lymphocytic | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2004-02-29 | 2018-01-23 |
| Immunotoxin in Treating Patients With Leukemia or Lymphoma LMB-2 immunotoxin - Leukemia, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 1996-04-01 | 2015-04-29 |
Leukemia (4) · Lymphoma (4) · Lymphoma, T-Cell, Cutaneous (3) · Burkitt Lymphoma (2) · Hodgkin Disease (2) · Leukemia, Hairy Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Mycosis Fungoides (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Sezary Syndrome (2) · Bronchiolitis Obliterans Syndrome (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Diseases (1)
National Cancer Institute (NCI) (6) · National Institutes of Health Clinical Center (CC) (2)
United States (8)
Robert J Kreitman, M.D. (4) · Robert Kreitman, MD (2) · Alan S. Wayne, MD (1) · Steven A. Rosenberg, MD, PhD (1)